{"url_path":"/sec/mane/8-k/2026-07-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1827635/0001827635-26-000023-index.html","accession_number":"0001827635-26-000023","cik":"0001827635","ticker":"MANE","issuer_name":"Veradermics, Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1827635/0001827635-26-000023-index.html","primary_entity_key":"0001827635","primary_entity_name":"Veradermics, Inc"},"word_count":178,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nOn July 15, 2026, Veradermics, Incorporated (the \"Company\") issued a press release announcing positive topline data from the Phase 2 clinical trial, ‘Study ‘207,’ evaluating VDPHL01 in females with mild-to-moderate pattern hair loss.\n\nA copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the presentation the Company presented on the conference call and webcast is furnished as Exhibit 99.2 to this Current Report on Form 8-K, and both are incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K and the Exhibits 99.1 and 99.2 furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing."}